These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 18535032)

  • 1. Seroprotection against serogroup C meningococcal disease in adolescents in the United Kingdom: observational study.
    Snape MD; Kelly DF; Lewis S; Banner C; Kibwana L; Moore CE; Diggle L; John T; Yu LM; Borrow R; Borkowski A; Nau C; Pollard AJ
    BMJ; 2008 Jun; 336(7659):1487-91. PubMed ID: 18535032
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antibody persistence after serogroup C meningococcal conjugate immunization of United Kingdom primary-school children in 1999-2000 and response to a booster: a phase 4 clinical trial.
    Perrett KP; Winter AP; Kibwana E; Jin C; John TM; Yu LM; Borrow R; Curtis N; Pollard AJ
    Clin Infect Dis; 2010 Jun; 50(12):1601-10. PubMed ID: 20459323
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Persistence of serum bactericidal antibody one year after a booster dose of either a glycoconjugate or a plain polysaccharide vaccine against serogroup C Neisseria meningitidis given to adolescents previously immunized with a glycoconjugate vaccine.
    de Whalley PC; Snape MD; Kelly DF; Banner C; Lewis S; Diggle L; John TM; Yu LM; Omar O; Borkowski A; Pollard AJ
    Pediatr Infect Dis J; 2011 Nov; 30(11):e203-8. PubMed ID: 21673612
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Investigation of serum bactericidal activity in childhood and adolescence 3-6 years after vaccination with a single dose of serogroup C meningococcal conjugate vaccine.
    Sakou II; Tzanakaki G; Tsolia MN; Sioumala M; Barbouni A; Kyprianou M; Papaevangelou V; Tsitsika A; Blackwell CC; Kafetzis D; Kremastinou J
    Vaccine; 2009 Jul; 27(33):4408-11. PubMed ID: 19500554
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term persistence of protective antibodies in Dutch adolescents following a meningococcal serogroup C tetanus booster vaccination.
    van Ravenhorst MB; Marinovic AB; van der Klis FR; van Rooijen DM; van Maurik M; Stoof SP; Sanders EA; Berbers GA
    Vaccine; 2016 Dec; 34(50):6309-6315. PubMed ID: 27817957
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Meningococcal serogroup A, C, W, and Y serum bactericidal antibody profiles in Hajj pilgrims.
    Memish ZA; Yezli S; Almasri M; Assiri A; Turkestani A; Findlow H; Bai X; Borrow R
    Int J Infect Dis; 2014 Nov; 28():171-5. PubMed ID: 25307887
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term seroprotection after an adolescent booster meningococcal serogroup C vaccination.
    de Whalley PC; Snape MD; Plested E; Thompson B; Nuthall E; Omar O; Borrow R; Pollard AJ
    Arch Dis Child; 2013 Sep; 98(9):686-91. PubMed ID: 23853000
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect on meningococcal serogroup W immunogenicity when Tdap was administered prior, concurrent or subsequent to the quadrivalent (ACWY) meningococcal CRM
    Tashani M; Badahdah AM; Alfelali M; Barasheed O; Alqahtani AS; Heron L; Wong M; Louth J; Rashid H; Borrow R; Booy R
    Vaccine; 2019 Jun; 37(27):3562-3567. PubMed ID: 31128875
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Meningococcal serogroup C immunogenicity, antibody persistence and memory B-cells induced by the monovalent meningococcal serogroup C versus quadrivalent meningococcal serogroup ACWY conjugate booster vaccine: A randomized controlled trial.
    van Ravenhorst MB; van der Klis FRM; van Rooijen DM; Knol MJ; Stoof SP; Sanders EAM; Berbers GAM
    Vaccine; 2017 Aug; 35(36):4745-4752. PubMed ID: 28668575
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunogenicity of the UK group B meningococcal vaccine (4CMenB) schedule against groups B and C meningococcal strains (Sched3): outcomes of a multicentre, open-label, randomised controlled trial.
    Davis K; Valente Pinto M; Andrews NJ; Goldblatt D; Borrow R; Findlow H; Southern J; Partington J; Plested E; Patel S; Holland A; Matheson M; England A; Hallis B; Miller E; Snape MD
    Lancet Infect Dis; 2021 May; 21(5):688-696. PubMed ID: 33428870
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Meningococcal serogroup B-specific responses after vaccination with bivalent rLP2086: 4 year follow-up of a randomised, single-blind, placebo-controlled, phase 2 trial.
    Marshall HS; Richmond PC; Beeslaar J; Jiang Q; Jansen KU; Garcés-Sánchez M; Martinón-Torres F; Szenborn L; Wysocki J; Eiden J; Harris SL; Jones TR; Lee SS; Perez JL;
    Lancet Infect Dis; 2017 Jan; 17(1):58-67. PubMed ID: 27745812
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Persistence of the immune response at 5 years of age following infant immunisation with investigational quadrivalent MenACWY conjugate vaccine formulations.
    Khatami A; Snape MD; Davis E; Layton H; John T; Yu LM; Dull PM; Gill CJ; Odrjlin T; Dobson S; Halperin SA; Langley JM; McNeil SA; Pollard AJ
    Vaccine; 2012 Apr; 30(18):2831-8. PubMed ID: 22394992
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evidence for Rise in Meningococcal Serogroup C Bactericidal Antibody Titers in the Absence of Booster Vaccination in Previously Vaccinated Children.
    Badahdah AM; Khatami A; Tashani M; Rashid H; Booy R
    Pediatr Infect Dis J; 2018 Mar; 37(3):e66-e71. PubMed ID: 29227467
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antibody persistence after serogroup C meningococcal conjugate vaccine in children with sickle cell disease.
    Souza AR; Maruyama CM; Sáfadi MA; Lopes MH; Azevedo RS; Findlow H; Bai X; Borrow R; Weckx LY
    Vaccine; 2016 Aug; 34(36):4327-34. PubMed ID: 27395566
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antibody kinetics following vaccination with MenAfriVac: an analysis of serological data from randomised trials.
    White M; Idoko O; Sow S; Diallo A; Kampmann B; Borrow R; Trotter C
    Lancet Infect Dis; 2019 Mar; 19(3):327-336. PubMed ID: 30745277
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Kinetics of Meningococcal Serogroup C-Specific Functional Antibody Levels Up to 15 Years after a Single Immunization with a Meningococcal Serogroup C Conjugate Vaccine during Adolescence.
    Stoof SP; van Ravenhorst MB; van Rooijen DM; de Voer RM; van der Klis FRM; Boland GJ; Sanders EAM; Berbers GAM; Teunis PF
    Clin Vaccine Immunol; 2017 Feb; 24(2):. PubMed ID: 27881489
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adolescent meningococcal serogroup A, W and Y immune responses following immunization with quadrivalent meningococcal A, C, W and Y conjugate vaccine: Optimal age for vaccination.
    van Ravenhorst MB; van der Klis FRM; van Rooijen DM; Sanders EAM; Berbers GAM
    Vaccine; 2017 Aug; 35(36):4753-4760. PubMed ID: 28647167
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effectiveness of meningococcal serogroup C vaccine programmes.
    Borrow R; Abad R; Trotter C; van der Klis FR; Vazquez JA
    Vaccine; 2013 Sep; 31(41):4477-86. PubMed ID: 23933336
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Analysis for protection rate and antibody levels of epidemic cerebrospinal meningitis among children aged between 3-23 months in Liuzhou, in 2012].
    Cui XL; Wu X; Li MQ
    Zhonghua Yu Fang Yi Xue Za Zhi; 2016 Dec; 50(12):1079-1083. PubMed ID: 28057112
    [No Abstract]   [Full Text] [Related]  

  • 20. Seroprevalence of antibodies against serogroup C meningococci in England in the postvaccination era.
    Trotter CL; Borrow R; Findlow J; Holland A; Frankland S; Andrews NJ; Miller E
    Clin Vaccine Immunol; 2008 Nov; 15(11):1694-8. PubMed ID: 18827191
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.